Salute e Benessere

Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading…

Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price.Islandsbanki will post bids and offers on the exchange amounting to at least ISK 8 million at market value at any given time at a price determined by Islandsbanki,...
Nasdaq GlobeNewswire
05/10/2023

Sleep Apnea Devices Market size worth USD 12.97 Billion, Globally, by 2030 at…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=25851 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=25851 Browse in-depth TOCon" Sleep Apnea Devices Market " 202 - Pages 126 – Tables 37 – Figures Global Sleep Apnea Market Research Report: A Comprehensive Insight into Market Dynamics, Growth Factors, and Key Players Sleep apnea, a widespread sleep disorder characterized by episodes of breathing...
PR Newswire
05/10/2023

Antibody Drug Conjugates (ADC) Market worth $19.8 billion | MarketsandMarkets

The major factors driving the growth of the market are collaborations & partnerships among market players operating in the market, increasing focus on the development of new ADCs and frequent approval from the FDA for new ADCs. Robust products under clinical studies and increased use of ADCs as combination therapy are likely to uplift market growth in coming years. The major factors driving the growth of the market are collaborations & partnerships among market players operating in…
PR Newswire
05/10/2023

Microfiber Synthetic Leather Market to register US$ 5,787.8 million by 2033 as…

The global market for microfiber synthetic leather is anticipated to expand at a 6.1% CAGR from 2023 to 2033. By the end of 2033, the microfiber synthetic leather market is anticipated to reach US$ 5,787.8 million. The global market for microfiber synthetic leather is anticipated to expand at a 6.1% CAGR from 2023 to 2033. By the end of 2033, the microfiber synthetic leather market is anticipated to reachUS$ 5,787.8 million. To gain insight into the Comprehensive Research...
PR Newswire
05/10/2023

Emerging Trends in the Nutraceuticals Industry | Future Market Insights, Inc.

Nutraceuticals Market Overview: Nutraceuticals Market Overview: Access an overview of the Comprehensive Research Report by downloading the Sample PDF Summary:https://www.futuremarketinsights.com/reports/sample/rep-gb-15103 The nutraceutical sales are set to keep growing. People like them because they are easy to store, can do many good things at once, and people are learning more about them. The popularity of nutraceutical products is going up fast. People are learning more...
PR Newswire
05/10/2023

Quotient Sciences Announces Successful US FDA Inspection of Alnwick, UK Facility

The regulatory inspection was conducted to audit three bioequivalence studies for three different insulin analogues for a renowned pharmaceutical company. The regulatory inspection was conducted to audit three bioequivalence studies for three different insulin analogues for a renowned pharmaceutical company. Quotient Sciences' Alnwick facility has specialty bioanalytical expertise and facilities for conducting bioequivalence studies, which play a crucial role in evaluating the similarity...
PR Newswire
05/10/2023

ESALON PROPELS ONLINE GLOBAL PRESENCE WITH HAIR COLOUR AND HAIR CARE LAUNCH ON…

"We strive to meet consumers where they are and create completely customer-focused hair journeys for them," said Greta Rose, CEO at eSalon. "There's been an increasing demand for our products on Amazon, so we are thrilled to introduce our technology-rooted hair colour and care offerings to broader audiences, directly in Amazon's store." "We strive to meet consumers where they are and create completely customer-focused hair journeys for them," saidGreta Rose, CEO at…
PR Newswire
05/10/2023

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that the Company received a letter (the “Notification Letter”) on September 29, 2023 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company's American Depositary Shares (“ADSs”) had closed below the minimum…
Nasdaq GlobeNewswire
05/10/2023

Discovery Life Sciences expands high-throughput proteomics services

The Olink platform delivers exceptional sensitivity and specificity for protein biomarker measurement. Olink Explore HT is the company's latest solution for high-throughput proteomics, allowing scientists to accurately measure over 5,300 proteins using only two microliters of sample. The Olink platform delivers exceptional sensitivity and specificity for protein biomarker measurement. Olink Explore HT is the company's latest solution for high-throughput proteomics, allowing scientists to...
PR Newswire
05/10/2023

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and…

~ Reduction of 28% of workforce not related to HEMGENIX ® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ Discontinuing investments in more than half of research and technology projects, centralizing operations, and streamlining organization ~~ Prioritizing continued development of AMT-130 in Huntington's disease and near-term initiation of clinical trials for AMT-260 in refractory mesial temporal lobe epilepsy,...
Nasdaq GlobeNewswire
05/10/2023

OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase…

Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial.The dropout rate is 5.4% and unrelated to side effects. Top-line efficacy and safety data are on schedule for release in December 2023.LONDON and NEW YORK, Oct.05, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical...
Nasdaq GlobeNewswire
05/10/2023

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023Lausanne, Switzerland, October 5, 2023– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023...
Nasdaq GlobeNewswire
05/10/2023

InDex Pharmaceuticals is attending the UEGW 2023 congress

The positive results from the pharmacokinetic (PK) study with cobitolimod was selected by UEGW as one of the best abstracts for poster presentation and will be presented by principal investigator Professor Per Hellström on October 15 at 10:30 CET on Poster Stage 1, during the moderated poster session: "Medical therapy of IBD: Facts and challenges." The positive results from the pharmacokinetic (PK) study with cobitolimod was selected by UEGW as one of the best abstracts for poster…
PR Newswire
05/10/2023

FRANK WARREN JOINS BOXWISE BOARD

Delivered entirely by certified England Boxing coaches, the free 10-week programme provides disadvantaged young people with a safe and controlled environment to channel their energies. It provides a break from any difficulties they may face outside, a free hot meal after each training session and an active pathways programme to help them move in the positive education/employment direction that best suits each individual. Delivered entirely by certified England Boxing coaches,the free 10-week...
PR Newswire
05/10/2023

European Medicines Agency Committee for Orphan Medicinal Products provides…

"We are pleased that the COMP has issued a positive opinion for orphan drug designation for setanaxib and are excited to start another clinical program in the renal space targeting an orphan indication where today there are no approved products," said CEO Renée Aguiar-Lucander. "We are pleased that the COMP has issued a positive opinion for orphan drug designation for setanaxib and are excited to start another clinical program in the renal space targeting an orphan indication…
PR Newswire
05/10/2023

XRP Healthcare & The Burnratty Investment Group on target for $100 Million…

The strategic partnership between XRP Healthcare and The Burnratty Investment Group signifies a monumental step towards advancing healthcare access and quality across the East African region. The strategic partnership between XRP Healthcare and The Burnratty Investment Group signifies a monumental step towards advancing healthcare access and quality across the East African region. "Our acquisition plan is a testament to our unwavering commitment to transforming healthcare inEast…
PR Newswire
05/10/2023

Biocomposites to host a symposium and present new STIMULAN® data at the European…

Specifically, the research findings have shown that: Specifically, the research findings have shown that: Biocomposites' symposium is to be livestreamed on 13 October and is entitled: "Local antibiotic delivery – a convincing concept for osteomyelitis, bone and soft tissue infection management "with Dr.Yvonne Achermann, Consultant in Orthopaedic Infections, and Mr.Robert Morley, Consultant Podiatric Surgeon, speaking on ' A clinical perspective of calcium sulphate use in...
PR Newswire
05/10/2023

Gedeon Richter: A new hope for treatment-resistant schizophrenia?

Treatment with clozapine is the gold standard when it comes to treatment-resistant schizophrenia (TRS). Nonetheless, partial response characterized by residual negative and cognitive symptoms is common. Cariprazine is a 3rd generation antipsychotic medication with a unique receptor profile and proven efficacy in persistent negative symptoms. The combination of these two antipsychotics might provide a viable solution for patients with insufficient response to clozapine, and according to the data…
PR Newswire
05/10/2023

XNK Therapeutics to present at 2nd Annual Innate Killer Europe Summit in October

On October 18, 2023, Dr. Maltais will present XNK and discuss how to harness autologous NK cells for personalized immunotherapy. She will discuss engineering vs non-engineering strategies, important aspects of repeat dosing as well as strategies to increase cell potency, targeting and persistence. OnOctober 18, 2023, Dr. Maltais will present XNK and discuss how to harness autologous NK cells for personalized immunotherapy. She will discuss engineering vs non-engineering strategies, important...
PR Newswire
05/10/2023

VALNEVA - Declaration of shares and voting rights: September 30, 2023

VALNEVADeclaration of shares and voting rights September 30 , 2023__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment BDeclaration date: October 5, 2023 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of...
Nasdaq GlobeNewswire
05/10/2023

Sobi appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Lydia Abad-Franch said: "I am very excited to lead the research, development, and medical teams at Sobi, where we have a strong portfolio of transformative medicines for people with rare diseases. I look forward to working with my colleagues across Sobi, our external partners, patients, and physicians to advance science and address critical unmet needs of patients with rare diseases." Lydia Abad-Franchsaid: "I am very excited to lead the research, development, and medical teams at…
PR Newswire
05/10/2023

Nexstim Receives NBS System 5 Order in Europe

Press release, Helsinki, 5 October 2023 at 9 AM (EEST) Nexstim Receives NBS System 5 Order in Europe Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 5 system. The end user is a new neurosurgery customer located in Europe.Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific...
Nasdaq GlobeNewswire
05/10/2023

Groupe Casino: Signing of the lock-up agreement relating to the financial…

Signing of the lock-up agreement relating to the financial restructuring of the Group with the secured creditorsOngoing discussions with unsecured creditorsUpdate on current trading Paris, 5 October 2023Casino Group announces that is has entered today into a lock-up agreement (the “ Lock-Up Agreement ”) relating to its financial restructuring, with, on the one hand EP Equity Investment III s.à r.l., an entity controlled by Mr. Daniel Křetínský, Fimalac and Attestor (hereafter...
Nasdaq GlobeNewswire
05/10/2023

Novartis to present new oncology data at ESMO 2023 demonstrating…

Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating Pluvicto TM (INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy setting for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)New analysis of key subgroups of clinical interest from NATALEE reinforces the potential of Kisqali ® (ribociclib) plus endocrine therapy (ET) to consistently reduce the risk of cancer...
Nasdaq GlobeNewswire
05/10/2023
Altri  Comunicati